We are creating the next generation of vaccines for our proprietary pipeline and for our partners’ pipelines. The company’s technologies (TetraExpress™, PRiSM™, and G-SOME™) are based upon Tetrahymena thermophila, a sophisticated microorganism that enables extremely rapid development and low-cost manufacture of vaccines that are more potent and easier to administer.
|
|
Our goal is to apply our technologies and scientific expertise to bring new and better vaccines to market for the prevention and treatment of a wide variety of human diseases. We are partnering with pharma companies to accelerate the development and commercialization of our novel vaccines and to enable the broader adoption of our technology for rapid vaccine development and manufacture. |
|
Our nanoparticle-based (G- SOME™) technology is applied to produce human vaccines that address a broad range of disease targets. We are focusing our internal development programs in the area of infectious diseases and are also working with strategic partners to create new products for other indications for which no effective vaccines exist to date. |
